Phase 3 trial, 885 patients with HER2-positive advanced breast cancer, prespecified interim analysis: estimated 24-month progression-free survival 58.5% with anbenitamab plus HB1801 vs 34.4% with THP (HR 0.46). Grade 3 or higher adverse events 45.9% vs 34.4%.
RCTn = 885
Wang et al. Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer